Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah M Jones

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Clinical and Translational Science|March 2, 2022
Estimation of brain receptor occupancy for trazodone immediate release and once a day formulationsLaura Oggianu, Giorgio Di Dato, Giorgina Mangano, et al.
Clinical and Translational Science|June 17, 2025
Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity PlanningAnanth Kadambi, Elke H J Krekels, Antal Martinecz, et al.
Journal of Theoretical Biology|December 5, 2012
A mathematical model of the human menstrual cycle for the administration of GnRH analoguesSusanna Röblitz, Claudia Stötzel, Peter Deuflhard, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2025
PBPK Modeling to Predict Clinical Drug-Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F-HydroxypropylamideNiyanta Kumar, Vaishali Dixit, Howard Burt, et al.
Clinical Pharmacology in Drug Development|March 27, 2025
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P-Glycoprotein InhibitionHongxia Jia, T Eric Ballard, Liming Zhang, et al.
Journal of Translational Medicine|August 22, 2014
Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cellsJiandong Wang, Xiaoli Ma, Hannah M Jones, et al.
Clinical Pharmacology and Therapeutics|November 16, 2023
Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for TucatinibIan E Templeton, Karen Rowland-Yeo, Hannah M Jones, et al.
The AAPS Journal|November 4, 2025
Investigating Sulfotransferase Mediated Drug Interactions of Ethinylestradiol using a Physiologically Based Pharmacokinetic ModelHarry P Moore, Kuan-Fu Chen, Aki T Heikkinen, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 22, 2013
Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyondHugh A Barton, Yurong Lai, Theunis C Goosen, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2026
Evaluation of the cytochrome P450-mediated drug interaction profile of olorofimKaren Cornelissen, John H Rex, Daniela Zinzi, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Clinical and Translational Science|March 2, 2022
Estimation of brain receptor occupancy for trazodone immediate release and once a day formulationsLaura Oggianu, Giorgio Di Dato, Giorgina Mangano, et al.
Clinical and Translational Science|June 17, 2025
Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity PlanningAnanth Kadambi, Elke H J Krekels, Antal Martinecz, et al.
Journal of Theoretical Biology|December 5, 2012
A mathematical model of the human menstrual cycle for the administration of GnRH analoguesSusanna Röblitz, Claudia Stötzel, Peter Deuflhard, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2025
PBPK Modeling to Predict Clinical Drug-Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F-HydroxypropylamideNiyanta Kumar, Vaishali Dixit, Howard Burt, et al.
Clinical Pharmacology in Drug Development|March 27, 2025
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P-Glycoprotein InhibitionHongxia Jia, T Eric Ballard, Liming Zhang, et al.
Journal of Translational Medicine|August 22, 2014
Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cellsJiandong Wang, Xiaoli Ma, Hannah M Jones, et al.
Clinical Pharmacology and Therapeutics|November 16, 2023
Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for TucatinibIan E Templeton, Karen Rowland-Yeo, Hannah M Jones, et al.
The AAPS Journal|November 4, 2025
Investigating Sulfotransferase Mediated Drug Interactions of Ethinylestradiol using a Physiologically Based Pharmacokinetic ModelHarry P Moore, Kuan-Fu Chen, Aki T Heikkinen, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 22, 2013
Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyondHugh A Barton, Yurong Lai, Theunis C Goosen, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2026
Evaluation of the cytochrome P450-mediated drug interaction profile of olorofimKaren Cornelissen, John H Rex, Daniela Zinzi, et al.
Pageof 10